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Treatment of diabetic nephropathy represents a signif-
icant economic burden, one that currently cannot be met
in many regions in the world. The incidence of diabetes
in the United States and Europe continues to rise, while
regions such as Asia, the Pacific, and Latin America are
facing a pandemic [1]. These regions do not have the med-
ical or financial resources necessary to face this burden.
In addition, present knowledge of the risk factor(s) that
contribute to progressive diabetic nephropathy is limited.
Therefore, the ability to identify those patients at high
risk of end-stage renal disease (ESRD), and the power to
focus therapeutic modalities to delay the progression to
ESRD, are severely lacking.
The RENAAL study represents a large repository of
clinical information that allows a greater understanding
of nephropathy in patients with type 2 diabetes. The
RENAAL study was initiated to investigate the long-
term renal protective role of losartan in patients (N =
1513) with type 2 diabetes and nephropathy [defined as
urinary albumin to creatinine ratio of 300 mg/g and serum
creatinine values greater than 1.3 mg/dL (female) and
1.5 mg/dL (male)]. Patients were randomized to ei-
ther losartan or placebo, with additional antihyperten-
sive medications added until the goal blood pressure of
<140/90 mm Hg was reached. Patients were followed
for a mean of 3.4 years. The population of RENAAL
was ethnically diverse, with Asians accounting for 17%,
blacks 15%, Hispanics 18%, and whites 48% of the pa-
tients. The study demonstrated that losartan, compared
with placebo, significantly reduced the incidence, and de-
layed the time to the composite outcome of a doubling of
serum creatinine concentration (DSCr), ESRD (defined
as the need for dialysis or transplantation), or death (risk
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reduction 16%, P = 0.02) [2]. RENAAL also demon-
strated for the first time that blockade of angiotensin II
by losartan delayed ESRD and the composite end point
of ESRD or death in these patients [2]. It is estimated that
the reduction in ESRD risk observed in the RENAAL
study corresponds to a 2-year delay in the need for dialy-
sis or transplantation [2], and represents a net reduction
in treatment costs of US $3522 per patient over 3.5 years
[3].
In an effort to identify those risk factors associated with
the progression of renal disease in patients with type 2 di-
abetes, analysis of 29 prespecified baseline characteristics
was performed [4, 5]. Analyses revealed that baseline pro-
teinuria (urine albumin:creatinine ratio) is the strongest
risk factor for ESRD, followed by baseline serum creati-
nine (SCr) and baseline hemoglobin [4]. Current findings
for the baseline factors associated with increased risk for
ESRD and their role in different ethnic groups from the
RENAAL study are presented here.
Baseline serum creatinine and the risk for ESRD
Assessment of renal function is critical in deter-
mining the rate of renal disease progression, and the
most commonly used method is measurement of SCr.
As expected, multivariate analyses of RENAAL data
demonstrated that baseline SCr was highly predictive of
increased risk of developing either a renal event (DSCr
or ESRD) or ESRD alone [4, 5]. SCr was also a good
predictor of ESRD in all ethnic groups (Fig. 1A). Losar-
tan reduced the risk of ESRD regardless of baseline
level of renal impairment (Fig. 1B). Patients with base-
line SCr levels ≥2.0 mg/dL similarly benefited from
losartan therapy to patients with baseline SCr levels
<2.0 mg/dL. This would suggest that losartan treatment
should be considered in patients with type 2 diabetes and
nephropathy, even in those with more advanced renal
disease.
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Fig. 1. Risk of end-stage renal disease associated with baseline serum
creatinine. (A) For each 1 mg/dL increase in baseline serum creati-
nine the following risk increase was observed (univariate analysis). (B)
Treatment effect of losartan vs. placebo by baseline serum creatinine.
Baseline proteinuria and the risk for ESRD
The level of proteinuria at baseline was highly predic-
tive of the primary composite end point, ESRD alone
and ESRD or death (Fig. 2A). In addition, baseline
proteinuria was shown to be the strongest risk predic-
tor for ESRD in Asians, blacks, Hispanics, and whites
(de Zeeuw, personal communication). In the RENAAL
study, baseline proteinuria was as predictive of ESRD as
was baseline SCr (Fig. 2B). To evaluate whether mod-
ification of this important risk factor by losartan was
associated with changes in outcome, de Zeeuw et al
[4] demonstrated that the reduction of proteinuria with
losartan during the initial 6 months of therapy in
RENAAL was a good predictor of ESRD outcome.
In the RENAAL study, losartan was associated with a
35% mean reduction in proteinuria (P < 0.001) [2]. The
reduction of proteinuria was observed across all ethnic
groups (de Zeeuw, personal communication), and was
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Fig. 2. Relationship between increasing baseline proteinuria and renal
outcome (A). Independence of baseline proteinuria with serum creati-
nine in predicting the development of end-stage renal disease (B).
greater than the reduction in proteinuria observed for
the placebo group. While reduction of proteinuria is as-
sociated with a decrease in risk of developing ESRD, it
does not fully account for the treatment effect of losar-
tan on reducing ESRD in the RENAAL study [6]. Only
∼50% of the risk reduction for ESRD was attributable to
a decrease in proteinuria [6], suggesting that additional
factors contribute to ESRD.
Baseline hemoglobin and the risk of ESRD
Anemia is common among patients with type 2 dia-
betes and nephropathy. Small studies have shown that
low hemoglobin levels are predictive of risk for pro-
gression of diabetic and nondiabetic nephropathy [7, 8].
In the RENAAL study, baseline hemoglobin concentra-
tions ranged from 6.8 g/dL to 18.0 g/dL, with a mean and
standard deviation of 12.5 ± 1.8 g/dL. Analysis of the
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Fig. 3. Risk of end-stage renal disease (ESRD) associated with base-
line hemoglobin (univariate analysis). (A) Risk of end-stage renal dis-
ease by baseline quartile of hemoglobin. (B) For each 1 g/dL decrease in
hemoglobin the following increase in risk was observed for each ethnic
group.
RENAAL study revealed that baseline hemoglobin was
an independent predictor of ESRD [9] and of renal
events (DScR or ESRD) [5]. Patients with lower base-
line hemoglobin concentrations had a greater preva-
lence of ESRD events, independent of their renal func-
tion and proteinuria levels, and the risk associated
with hemoglobin levels increased as hemoglobin con-
centration decreased (Fig. 3A) [9]. In addition, baseline
hemoglobin was a good predictor of ESRD in all ethnic
groups (Fig. 3B).
Additional risk factors associated with ESRD
Reduction of blood pressure (BP) is recognized as
an important mechanism in delaying the progression of
renal disease [10]. The RENAAL study adopted a BP
goal of ≤140/90 mm Hg based on current, applicable
guidelines at the time of study inception. Multivariate
analysis demonstrated that baseline BP was not an inde-
pendent risk factor for the development of ESRD in the
RENAAL study. However, baseline BPs of ≤140/90 mm
Hg were associated with decreased risk of ESRD, lending
support to a relationship between lower BP and reduced
ESRD risk [11].
Losartan was demonstrated to reduce the risk of ESRD
regardless of whether goal BP was achieved (risk reduc-
tion 28%, P = 0.002) [11]. Nonetheless, in those patients
who achieved a goal systolic BP of <140 mm Hg, losar-
tan treatment was associated with a 34% risk reduction
(P = 0.03) [11]. These data highlight that achieving goal
BP is important; however, blockade of angiotensin II by
losartan provides additional benefit over blood pressure
reduction alone.
Studies in animal models suggest a relationship be-
tween hyperlipidemia and progression of renal disease
[12]. In addition, small studies in humans allude to a
potential role for hyperlipidemia in progressive renal
disease [13, 14]. Baseline low-density lipid cholesterol
(LDL) was associated with an increased risk of devel-
oping ESRD in the RENAAL study [15]. This effect was
most apparent in patients whose baseline LDL was >167
mg/dL (HR 2.48, P < 0.001) [15]. While these data are
tantalizing, further elucidation of the role of hyperlipi-
demia, either as a primary risk or as a correlated factor
with proteinuria, in the progression of renal disease is
required.
CONCLUSION
RENAAL is the first study to demonstrate that an-
giotensin II antagonism with losartan is renal protective
by delaying the onset of ESRD in patients with type 2
diabetes and nephropathy. Baseline proteinuria, serum
creatinine, and hemoglobin were identified as indepen-
dent predictors of increased risk of ESRD in all patients,
regardless of ethnic origin. The similar risks seen in ethni-
cally diverse patients, and the positive treatment effect of
losartan, suggest that losartan therapy may be an impor-
tant part of the treatment strategy for patients with type
2 diabetes and nephropathy. Additionally, the projected
delay in the need for dialysis or transplantation, and
the reduction in patient treatment costs associated with
losartan, has major socioeconomic importance, particu-
larly in countries were renal replacement therapies are
limited.
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